What is AYTU's P/E ratio?

AYTU BIOSCIENCE INC (AYTU) currently trades at a P/E ratio of 11.74.

AYTU BIOSCIENCE INC reports a Return on Equity (ROE) of -96.90%.

What is AYTU's dividend yield?

AYTU BIOSCIENCE INC offers a dividend yield of 0.00%.

What is AYTU's Quality Score?

Our AI rates AYTU's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy AYTU?

Our AI Timing Score for AYTU is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does AYTU belong to?

AYTU BIOSCIENCE INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

AYTU (NASDAQ) Stock Analysis | AYTU BIOSCIENCE INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

AYTU AI Analysis Summary

Our AI summary for AYTU: AYTU BIOSCIENCE INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 11.74, ROE of -96.90%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

AYTU

AYTU BIOSCIENCE INC

USD 2.23

0.08 (3.72%) Day Change

Watchlist Portfolio Compare Chart

11.74

P/E

0.63

D/E

-96.9%

ROE

-30.5%

ROA

0.00%

Div Yield

-0.22

PEG

AYTU BIOSCIENCE INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.23 Price 0.08 (3.72%) Day Change	NEWS SCORE: 94

AYTU, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.23
PBV / Sector	0.66 / 3.22 GREAT
Earning Per Share	-3.29

PE / Sector	11.74 / 29.79 GOOD
PEG or PE/Growth / Sector	-0.22 / 0.13
Average 1M Daily Value	0.06 M GREAT
Average 1W Daily Value	0.08 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-60.17 / 15.21
NPM Average (%) / Sector	-46.66 / -10.83
NPM Change Average (%) / Sector	36.44 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-30.49 / 8.15
ROA Average (%) / Sector	-29.23 / 2.87
ROA Change Average (%) / Sector	21.13 / 112.70 GREAT
ROE (%) / Sector	-96.90 / -1.02
ROE Average (%) / Sector	-102.88 / 8.35
ROE Change Average (%) / Sector	2.55 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 07:59:31
Symbol	AYTU
Name	AYTU BIOSCIENCE INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	10.73 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	23.08 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Denver Corporate Center III, Denver, CO, United States, 80237

Phone: 720 437 6580

Website: https://aytubio.com

Employees: 82

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.